ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "treatment"

  • Abstract Number: 1429 • 2019 ACR/ARP Annual Meeting

    Results at 6 Months of Abatacept vs TNF-α Blockers in Patients with Severe, Long-standing, DMARDs Resistant Rheumatoid Arthritis

    Omar Valenzuela 1, Sebastian Ibanez2, Maria Paz Poblete 3, Claudia Mardones 2, Francisco Silva 2, Maria Jose Villar 2 and Katherine Mogollones 1, 1Facultad de Medicina Clinica Alemana -UDD, Santiago, Region Metropolitana, Chile, 2Facultad de Medicina Clinica Alemana - UDD, Santiago, Region Metropolitana, Chile, 3Rheumatology dpt., Facultad de Medicina Clinica Alemana - UDD, Santiago, Region Metropolitana, Chile

    Background/Purpose: Since January 2016, Chilean patients with rheumatoid arthritis (RA), with severe activity despite the use of 3 DMARDs for at least 6 months, have guaranteed access…
  • Abstract Number: 2381 • 2019 ACR/ARP Annual Meeting

    Baseline Characteristics Associated with Sustained SDAI Remission Following Treatment with Abatacept in Combination with MTX Compared with Abatacept Placebo in Combination with MTX in ACPA Positive Patients with Early RA

    Paul Emery1, Yoshiya Tanaka 2, Vivian Bykerk 3, Clifton Bingham 4, Thomas Huizinga 5, Gustavo Citera 6, Kuan-Hsiang Gary Huang 7, Sean Connolly 7, Yedid Elbez 8, Karissa Lozenski 9 and Roy Fleischmann 10, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Hospital for Special Surgery, New York City, NY, 4Johns Hopkins University, Baltimore, MD, 5Leiden University Medical Center, Leiden, Netherlands, 6Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 7Bristol-Myers Squibb, Princeton, NJ, 8Excelya, Boulogne-Billancourt, France, 9Bristol-Myers Squibb, Princeton, 10Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: The Phase IIIb Assessing Very Early Rheumatoid arthritis Treatment (AVERT)-2 trial (NCT02504268) is evaluating SC abatacept (ABA) + MTX versus ABA placebo (PBO) +…
  • Abstract Number: 515 • 2019 ACR/ARP Annual Meeting

    Clinical Responses in Patients with Inadequate Response to bDMARDs upon Treatment with Upadacitinib

    Michael Weinblatt1, Glen Thomson 2, Kun Chen 3, Sebastian Meerwein 4, Casey Schlacher 5 and John Cush 6, 1Brigham and Women's Hospital, Boston, MA, USA, Boston, MA, 2CIADS Research, Winnipeg, Canada, 3AbbVie Inc., North Chicago, 4AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, 5AbbVie Inc., North Chicago, IL, 65Baylor University Medical Center, Dallas

    Background/Purpose: Upadacitinib (UPA), a JAK1-selective inhibitor, demonstrated efficacy in the SELECT-BEYOND study in patients (pts) with moderate to severe rheumatoid arthritis (RA) on a stable…
  • Abstract Number: 1138 • 2019 ACR/ARP Annual Meeting

    Outpatient Costs and Evaluation and Management (E&M) Expenditure Trends in Rheumatoid Arthritis (RA) Patients Treated with Biologic Therapies in US Community Practices

    Colin Edgerton1, Janna Radtchenko 2 and V. Michael Holers 3, 1Articularis Healthcare, Charleston, 2Trio Health, La Jolla, CA, 3University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver

    Background/Purpose: RA is an autoimmune disease affecting over 1.5 million Americans. Biologic disease-modifying antirheumatic drugs (bDMARDs) expanded treatment choices for RA patients (pts) in the…
  • Abstract Number: 1432 • 2019 ACR/ARP Annual Meeting

    Tapering and Discontinuing Prednisolone Without Deteriorated Disease Control by Optimizing Methotrexate in Patients with Rheumatoid Arthritis Under Stable Treatment – 2-year Results in the Real-world Clinical Practice –

    Shintaro Hirata1, Takuji Omoto 1, Hiroki Kohno 1, Hirofumi Watanabe 1, Kazutoshi Yukawa 1, Tadahiro Tokunaga 1, Tatsuomi Kuranobu 1, Katsuhiro Oi 1, Yusuke Yoshida 1, Tomohiro Sugimoto 1, Sho Mokuda 1, Keisuke Oda 1, Takaki Nojima 1 and Eiji Sugiyama 1, 1Hiroshima University, Hiroshima, Japan

    Background/Purpose: To determine whether prednisolone (PSL) could be tapered or discontinued without deterioration of disease control through optimizing methotrexate (MTX) for 2-yrs in patients with…
  • Abstract Number: 2402 • 2019 ACR/ARP Annual Meeting

    Which Factors Influence Achievement of Treatment Satisfaction in Rheumatoid Arthritis?

    Martin Schaefer1, Jörn Kekow 2, Karin Rockwitz 3, Anke Liebhaber 4, Angela Zink 5 and Anja Strangfeld 6, 1German Rheumatism Research Center, Berlin, Germany, 2Otto von Guericke University Magdeburg and Helios Clinic Vogelsang-Gommern, Vogelsang-Gommern, Germany, 3Rheumatologist, Goslar, Germany, 4Rheumatologist, Halle/ Salle, Germany, 5German Rheumatism Research Centre and Charité University medicine, Berlin, Germany, 6German Rheumatism Research Center (DRFZ), Berlin, Germany

    Background/Purpose: The satisfaction of rheumatoid arthritis (RA) patients with their pharmacological therapy is a relevant patient reported outcome which influences treatment adherence and continuation. However,…
  • Abstract Number: 517 • 2019 ACR/ARP Annual Meeting

    A Subgroup Analysis of Clinical Efficacy Response and Quality of Life Outcomes from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs

    Mark Genovese1, Kurt de Vlam 2, Jacques-Eric Gottenberg 3, Beatrix Bartok 4, Iyabode Tiamiyu 4, Ying Guo 4, Chantal Tasset 5, John Sundy 4, David Walker 6, Tsutomu Takeuchi 7 and Kenneth Kalunian 8, 1Stanford University, Stanford, CA, 2Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, 3Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 4Gilead Sciences, Inc., Foster City, CA, 5Galapagos NV, Mechelen, Belgium, 6Northumbria Healthcare, Northumbria, United Kingdom, 7Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, 8Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA

    Background/Purpose: There is an unmet medical need to treat RA in patients who have failed prior biologic DMARD treatments (biologic DMARD inadequate response; bDMARD-IR), some…
  • Abstract Number: 1193 • 2019 ACR/ARP Annual Meeting

    EMR-integrated Disease Activity Calculators Improve Treatment to Target in Rheumatoid Arthritis

    Gabrielle Barbera1, Jasleen Kahlon 2, Manank Patel 3, Scott Pompa 4 and Arundathi Jayatilleke 1, 1Drexel, Philadelphia, PA, 2Hahnemann, Philadelphia, PA, 3Rutgers, New Brunswick, NJ, 4Dartmouth, Lebanon, NH

    Background/Purpose: Undertreatment of RA can lead to cumulative joint damage as well as negatively impact emotional health. Recent evidence favors a treat-to-target strategy to achieve…
  • Abstract Number: 1437 • 2019 ACR/ARP Annual Meeting

    Comparison of the Efficacy and Safety of Abatacept in Rheumatoid Arthritis Patients with and Without Interstitial Lung Disease

    Sho Sasaki1, Akira Ishii 2, Mai Sugiyama 2, Yuto Izumi 2, Yoko Nakagome 2, Kazuki Hirano 3, Takayoshi Kurabayashi 1, Noriko Sasaki 2, Chiho Yamada 2 and Shinji Sato 4, 1Tokai Universitiy School of Medicine, Isehara, Japan, 2Tokai University School of Medicine, Isehara, Japan, 3Tokai University School of Medicine, Isehara, 4Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Yokohama, Japan

    Background/Purpose: Interstitial lung disease (ILD) is one of complication in patients with rheumatoid arthritis (RA) and its presence often has an effect on the management…
  • Abstract Number: 2403 • 2019 ACR/ARP Annual Meeting

    Adverse Events of Special Interest in Patients with Rheumatoid Arthritis Treated with Peficitinib in Asian Population: Pooled Safety Findings

    Tsutomu Takeuchi1, Yoshiya Tanaka 2, Mitsuhiro Rokuda 3, Hiroyuki Izutsu 3, Yuichiro Kaneko 3, Musashi Fukuda 3 and Daisuke Kato 3, 1Keio University School of Medicine, Tokyo, Japan, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Astellas Pharma, Inc., Tokyo, Japan

    Background/Purpose: Peficitinib, a novel oral Janus kinase (JAK) inhibitor, has demonstrated efficacy in studies of Japanese, Korean and Taiwanese patients with RA. This analysis of…
  • Abstract Number: 518 • 2019 ACR/ARP Annual Meeting

    Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological DMARDs: Results at 60 Weeks

    Mark Genovese1, Bernard Combe 2, Stephen Hall 3, Andrea Rubbert-Roth 4, Sheng Zhong 5, Sebastian Meerwein 6, Aileen Pangan 7 and Roy Fleischmann 8, 1Stanford University, Stanford, CA, 2CHU Montpellier, Montpellier University, Montpellier, France, 3Monash University and Emeritus Research, Melbourne, Australia, 4Kantonsspital St. Gallen, St Gallen, Switzerland, 5AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, 6AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, 7AbbVie Inc., North Chicago, 8Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: In patients (pts) with active rheumatoid arthritis (RA) and inadequate response or intolerance to bDMARDs, treatment with upadacitinib (UPA), a JAK1-selective inhibitor resulted in…
  • Abstract Number: 1302 • 2019 ACR/ARP Annual Meeting

    Subcutaneous Tanezumab vs NSAID for the Treatment of Osteoarthritis: Efficacy and General Safety Results from a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study

    Marc C. Hochberg1, John Carrino 2, Thomas Schnitzer 3, Ali Guermazi 4, Eric Vignon 5, David Walsh 6, Alexander White 7, Satoru Nakajo 8, Robert Fountaine 9, Anne Hickman 9, Glenn Pixton 10, Lars Viktrup 11, Mark T. Brown 9, Christine R. West 9 and Kenneth M. Verburg 9, 1University of Maryland School of Medicine, Baltimore, MD, 2Hospital for Special Surgery, New York, NY, 3Northwestern University Feinberg School of Medicine, Chicago, IL, 4Boston Medical Center, Boston, 5Université Claude Bernard Lyon 1, Lyon, France, 6Sherwood Forest Hospitals NHS Foundation Trust, Nottingham, United Kingdom, 7Progressive Medical Research, Port Orange, FL, 8Nakajo Orthopaedic Clinic, Miyagi, Japan, 9Pfizer Inc, Groton, CT, 10Pfizer Inc, Morrisville, NC, 11Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: Tanezumab is a monoclonal antibody that inhibits nerve growth factor and is under investigation for chronic pain treatment. Tanezumab administered intravenously was effective and…
  • Abstract Number: 1438 • 2019 ACR/ARP Annual Meeting

    Discontinuation of Concomitant Methotrexate in Japanese Patients with Rheumatoid Arthritis Treated with Tocilizumab: An Interventional Study

    Toshihisa Kojima1, Shuji Asai 1, Masahiro Hanabayashi 2, Masatoshi Hayashi 3, Nobunori Takahashi 1, Yachiyo Kuwatsuka 4, Masahiko Ando 4 and Naoki Ishiguro 1, 1Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Ichinomiya Municipal Hospital, Ichinomiya, Japan, 3Hayashi Orthopedic Clinic, Nagano, Japan, 4Nagoya University Hospital, Nagoya, Japan

    Background/Purpose: Biological DMARD (bDMARD) concomitant with methotrexate (MTX) has made great progress in the treatment of rheumatoid arthritis (RA) in these decades. There are various…
  • Abstract Number: 2536 • 2019 ACR/ARP Annual Meeting

    Distribution and Predictors of Whole Blood Hydroxychloroquine Levels in Clinical Rheumatology Practices in the United States

    Thierry Dervieux1, Kelley Brady 1, Don Thomas 2, John Conklin 1, Eugene Fung 3, Claudia Ibarra 1 and Michelle Petri 4, 1Exagen, Vista, CA, 2Walter Reed National Military Medical Center, Bethesda, MD, 3Arthritis & Osteoporosis Clinic, Waco, TX, 4Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Therapeutic drug monitoring of whole blood Hydroxychloroquine (HCQ) can help identify patients at risk of flares due to underexposure (e.g. severe non-adherence, < 200…
  • Abstract Number: 522 • 2019 ACR/ARP Annual Meeting

    Treatment with Upadacitinib Results in the Normalization of Key Pathobiologic Pathways in Patients with Rheumatoid Arthritis

    Thierry Sornasse1, Jeremy Sokolove 1 and Iain McInnes 2, 1AbbVie Immunology Clinical Development, Redwood City, 2Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor selective for JAK1, demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA) with an inadequate response (IR) to…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 22
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology